|
|
|
|
|
|
|
|
abstract
November 23, 2016.
This manuscript reports the consensus
statements regarding recurrent ovarian cancer (ROC), reached at the 5th
Ovarian Cancer
Consensus Conference (OCCC), which was held in
Tokyo, Japan, in November 2015. Three important questions were
identified:
(1) What are the subgroups for clinical trials in
ROC? The historical definition of using platinum-free interval (PFI) to
categorize patients as having
platinum-sensitive/resistant disease was replaced by therapy-free
interval (TFI). TFI can be
broken down into TFIp (platinum-free interval),
TFInp (non-platinum-free interval) and TFIb (biological agent-free
interval).
Additional criteria to consider include histology,
BRCA mutation status, number/type of previous therapies, outcome of
prior
surgery and patient reported symptoms. (2) What are
the control arms for clinical trials in ROC? When platinum is
considered
the best option, the control arm should be a
platinum-based therapy with or without an anti-angiogenic agent or a
poly (ADP-ribose)
polymerase (PARP) inhibitor. If platinum is not
considered the best option, the control arm could include a non-platinum
drug,
either as single agent or in combination. (3) What
are the endpoints for clinical trials in ROC? Overall survival (OS) is
the preferred endpoint for patient cohorts with an
expected median OS less than or equal to 12 months. Progression-free
survival
(PFS) is an alternative, and it is the preferred
endpoint when the expected median OS is more than 12 months. However,
PFS
alone should not be the only endpoint and must be
supported by additional endpoints including predefined patient reported
outcomes (PROs), time to second subsequent therapy
(TSST), or time until definitive deterioration of quality of life
(TUDD).
0 comments :
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.